ASTRIA THERAPEUTICS INC
NASDAQ: ATXS (Astria Therapeutics, Inc.)
Last update: 1 hour ago7.37
-0.06 (-0.81%)
| Previous Close | 7.43 |
| Open | 7.56 |
| Volume | 457,861 |
| Avg. Volume (3M) | 297,441 |
| Market Cap | 415,925,216 |
| Price / Book | 2.54 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 17.39 |
| Operating Cash Flow (TTM) | -96.14 M |
| Levered Free Cash Flow (TTM) | -62.11 M |
| Return on Assets (TTM) | -22.56% |
| Return on Equity (TTM) | -32.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Astria Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 106.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Jun 2025 | 4,107,537 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (JMP Securities, 252.78%) | Buy |
| Median | 21.00 (184.94%) | |
| Low | 16.00 (HC Wainwright & Co., 117.10%) | Buy |
| Average | 21.00 (184.94%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Aug 2025 | 16.00 (117.10%) | Buy | 6.87 |
| JMP Securities | 13 Aug 2025 | 26.00 (252.78%) | Buy | 6.87 |
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 |
| 27 Aug 2025 | Announcement | Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference |
| 12 Aug 2025 | Announcement | Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update |
| 06 Aug 2025 | Announcement | Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan |
| 07 Jul 2025 | Announcement | Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit |
| 18 Jun 2025 | Announcement | Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |